RxDoctor Payments Data

Nicholas Banker

Psychiatric/Mental Health · New York, NYNPI 1770060071

Payments from drug & device makers

$6,957in general payments, 2019–2025

Across 392 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Alkermes, Inc.$661
  • Lundbeck LLC$600
  • Neurocrine Biosciences, Inc.$567
  • Takeda Pharmaceuticals U.S.A., Inc.$469
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,91099%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,957 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$78,333
Medicare patients
104
Services billed
745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuvelityDextromethorphan Hbr/Bupropion29$33,367
VraylarCariprazine Hcl16$32,410
QelbreeViloxazine Hcl12$11,630
TrintellixVortioxetine Hydrobromide16$11,123
VyvanseLisdexamfetamine Dimesylate13$4,633
Bupropion XlBupropion Hcl99$2,810
Duloxetine Hcl53$1,544
Desvenlafaxine Succinate ErDesvenlafaxine Succinate17$1,398
Mirtazapine52$888
Fluoxetine Hcl25$802
Trazodone Hcl35$733
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine31$662
Sertraline Hcl46$641
Guanfacine Hcl ErGuanfacine Hcl24$611
Lamotrigine35$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Auvelity$285$33,36729 claims
AbbVieVraylar$1,198$32,41016 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$469$15,75629 claims
Supernus Pharmaceuticals, Inc.Qelbree$84$11,63012 claims
Almatica Pharma LLCSertraline Hcl$31$64146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →